Page 440 - Read Online

Page 14 of 15 Klaas et al. J Cancer Metastasis Treat 2023;9:23 https://dx.doi.org/10.20517/2394-4722.2022.125

27. Kim DS, Camacho CV, Kraus WL. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp
Mol Med 2021;53:42-51. DOI PubMed PMC
28. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian
carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.
DOI
29. Spring LM, Nakajima E, Hutchinson J, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and
management of potential toxicities. Oncologist 2021;26:827-34. DOI PubMed PMC
30. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012
study. J Clin Oncol 2016;34:2460-7. DOI PubMed PMC
31. Thomas R, Al-Khadairi G, Decock J. Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future
prospects. Front Oncol 2020;10:600573. DOI PubMed PMC
32. Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med
2022;387:217-26. DOI
33. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med
2018;379:2108-21. DOI
34. Miles D, Gligorov J, André F, et al. LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase
III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer
(mTNBC). Ann Oncol 2020;31:S1147-8. DOI
35. Wambeke S, Gyawali B. Atezolizumab in metastatic triple-negative breast cancer-no contradiction in the eyes of a dispassionate
observer. JAMA Oncol 2021;7:1285-6. DOI PubMed
36. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 2011;13:221. DOI PubMed PMC
37. Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol 2013;10:494-506. DOI PubMed
38. Gao JJ, Swain SM. Luminal A breast cancer and molecular assays: a review. Oncologist 2018;23:556-65. DOI PubMed PMC
39. Treatment by cancer type. Available from: https://www.nccn.org/guidelines/category_1 [Last accessed on 13 June 2023].
40. Bailleux C, Eberst L, Bachelot T. Treatment strategies for breast cancer brain metastases. Br J Cancer 2021;124:142-55. DOI
PubMed PMC
41. Hosonaga M, Saya H, Arima Y. Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis
Rev 2020;39:711-20. DOI PubMed PMC
42. Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets.
Semin Cancer Biol 2020;60:14-27. DOI
43. Lah TT, Novak M, Breznik B. Brain malignancies: glioblastoma and brain metastases. Semin Cancer Biol 2020;60:262-73. DOI
PubMed
44. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-96.
DOI PubMed PMC
45. Pedrosa RMSM, Mustafa DA, Soffietti R, Kros JM. Breast cancer brain metastasis: molecular mechanisms and directions for
treatment. Neuro Oncol 2018;20:1439-49. DOI PubMed PMC
46. Shah N, Mohammad AS, Saralkar P, et al. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of
breast cancer brain metastases. Pharmacol Res 2018;132:47-68. DOI PubMed PMC
47. Venishetty VK, Geldenhuys WJ, Terell-Hall TB, et al. Identification of novel agents for the treatment of brain metastases of breast
cancer. Curr Cancer Drug Targets 2017;17:479-85. DOI PubMed PMC
48. Knier NN, Pellizzari S, Zhou J, Foster PJ, Parsyan A. Preclinical models of brain metastases in breast cancer. Biomedicines
2022;10:667. DOI PubMed PMC
49. Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast
cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol 2020;38:3138-49. DOI
50. Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated
HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol
2022;33:321-9. DOI
51. Deng J, Chernikova SB, Wang Y, et al. A novel brain-permeant chemotherapeutic agent for the treatment of brain metastasis in triple-
negative breast cancer. Mol Cancer Ther 2021;20:2110-6. DOI PubMed PMC
52. Oehrlich NE, Spineli LM, Papendorf F, Park-Simon TW. Clinical outcome of brain metastases differs significantly among breast
cancer subtypes. Oncol Lett 2017;14:194-200. DOI PubMed PMC
53. Peyrat JP, Bonneterre J, Hecquet B, et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J
Cancer 1993;29A:492-7. DOI
54. Law JH, Habibi G, Hu K, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and
is related to poor survival. Cancer Res 2008;68:10238-46. DOI
55. Hwang KT, Kim EK, Jung SH, et al. Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a
study based on nationwide Korean Breast Cancer Registry database. Breast Cancer Res Treat 2018;169:311-22. DOI
56. Bergen ES, Berghoff AS, Steindl A, et al. Androgen receptor is expressed in breast cancer brain metastases. Appl Immunohistochem
Mol Morphol 2021;29:728-33. DOI